|
|
| April
23 |
Håkan Widner: Shopping for the right
cell to graft.
Introduction by Olle Lindvall
Cell based therapy for neurologicl disorders have the potential
to become an important treatment alternative. The best example
is in Parkinson's disease (PD), but cell transplantation in
other disorders such as demyelinating conditions, stroke and
Huntington's disease have already been attempted. The clinical
effects limitations of of neural grafting in PD and other
disorders will be briefly reviewed.
For neural repair to be successful, transplanted neurons so
far have had to be embryonic and this has limited the application
of neural tissue transplantation.
In vitro expansion of pleuropotent progenitors or other types
of cells, and in vitro controlled differentiation to a defined
cell population are being envisioned as future limitless cell
sources. In the Parkinson's disease case, the envisioned cell
type should be a dopamine producing neuron. However, from
the clinicians point of view, there are more requirements
prior to a cell to be transplantated and the fine print and
detailed specification on the properties of the cell to be
implanted will be outlined and discussed. Some aspects of
the regulatory aspects for a commercial type of cell will
also be discussed.
Refs: Widner H. Translantation of neuronal and non-neuronal
cells into the brain. Chapter 11 in Immune and Inflammatory
respones in the nervous system. NJ Rothwell Bios Scientific
Publ, 2002
Brevig T, Holgersson J, Widner H. Xenotransplantation for
CNS repair: immunological barriers and strategies to overcome
them. Trends in Neuroscience, 23: 337-344, 2000.
Widner H. The case FOR embryonic neural tissue transplantation
as a therapy for Parkinson's disease. Advances in Neurology;
80 641-650, 1999.
|
| May
7 |
Markus Ringner: Analysing microarray data with
Application from cancer studies. Introduction by Carsten Petersson
As more and more data sets from high-throughput technologies
become available, analysis methods that combine information
from many sources will be very useful to extend the results
obtainable from one data set. Strategies for analysing microarray
data from several sources or platforms will be presented.
The methods will be illustrated with applications for investigating
i) the impact of gene copy number changes on gene expression,
and ii) if one can link genes found to be relevant in a comprehensive
study of hormone and growth signaling pathways in breast cancer
to disease progression through previously published breast
tumor expression studies.
|
| May
14 |
Bengt Juliusson: Generaton of human neural
progenitor cell lines. Inroduction by Anders Björklund
Cell based transplantation therapy has the potential to become
an alternative treatment for Parkinson's disease. We are evaluating
the possibility to use region specific immortalized human
neural cell lines as a source of cells for such a therapy.
The procedure for generating cell lines is described by the
following five steps.
1) Establishment of primary cell cultures from fetal human
ventral mesencephalon.
2) Transduction of cells with a retroviral vector containing
v-myc as the immortalizing gene.
3) Expansion of cell lines and subcloning into clonal cell
lines.
4) Characterization of cells to select cell lines with a dopaminergic
phenotype.
5) Evaluation of the therapeutic potential of the cell lines
after transplantation to animal models for Parkinson's disease.
The generated cell lines can also serve as tools in gene expression
studies to discover new therapeutic factors.
Review article: Martinez-Serrano A, Rubio FJ, Navarro B,
Bueno C, Villa A Human neural stem and progenitor cells: in
vitro and in vivo properties, and potential for gene therapy
and cell replacement in the CNS. Curr Gene Ther 2001 Sep;1(3):279-99
|
| May
21 |
Mikael Sigvardsson: Molecular mechanisms
in adipocyte differentiation. Introduction by Stefan Karlsson
Adipocyte progenitors develop already in the early embryo
and are of key importance for the metabolic homeostasis in
both humans and mice. The molecular mechanisms that stimulate
the development of these cells from mesenchymal stem cells
and fibroblastic cells has been under detailed investigation
using in vitro differentiation systems. This work has resulted
in the identification of a number of transcription factors
with important roles this process. Among these are the PPARgs
as well as the C/EBP proteins a, b and d. Two other proteins
that are suggested to play roles in adipogenesis are the helix-loop-helix
proteins ADD1/SREBP and EBF-1/OE-1. EBF is expressed at the
earliest stages of differentiation but in contrast to the
C/EBP b and d proteins, who themselves are rather poor stimulators
of terminal adipogenisis in vitro, EBF-1 is able to induce
the adipogenic program in fibroblasts with a kinetic and efficiency
comparable to that of PPARg2. Ectopic expression of EBF-1
induced adipocyte differentiation of NIH 3T3 fibroblasts and
was also able to enhance adipogenesis in 3T3-L1 cells as well
as in mouse embryonic fibroblasts. To gain a deeper insight
into the molecular mechanisms involved in adipogenesis, we
analysed the differences in mRNA levels, in NIH 3T3 infected
either with an empty retrovirus or cells infected with viruses
harbouring PPARg2 or EBF-1 cDNA, using Affymetrix DNA microarrays.
Cell culture RNA was harvested and analyzed 5-6 days after
retroviral infection, before addition of hormonal stimulators
of adipogenesis, and at several time points after hormonal
induction of differentiation. The initial expression profiles
obtained differed between EBF-1 and PPARg2 induced adipogenesis
and the similarities in RNA expression did not become apparent
until day 4 after induction of differentiation by the addition
of external stimuli. At this time, not only the transcription
factor induced, but also the vector transduced control cells
expressed significant amounts of fat cell related genes. However,
while the expressing of these marker genes were further increased
in the EBF or PPARg at day 10 after stimulation, their expression
declined in the vector transduced cells suggesting that commitment
to adipogenic cell fate occurred after a global activation
of adipocyte related genes. The initial differential gene
expression pattern in the trancription factor transduced cells
was also reflected in that EBF-1 transduced cells had the
potential to differentiate into adipocytes in the absence
of insulin, while this was necessary for significant amounts
of PPARg induced adipogenesis. This discrepancy between EBF-1
and PPARg2 might be explained by the finding that EBF-1 appear
to enhance the expression of insulin like growth factor 2
possibly by direct interaction with enhancer elements 3' of
this gene. We do not know if the induction of IGFII transcription
explain the differential requirement of external stimuli in
the adipocyte differentiation pathways but the identification
of the IGFII/H19 locus as a potential EBF-1 target gene provides
a possible clue to novel functions of EBF proteins also in
embryogenesis and tumorogenisis.
Recommended reading
Akerblad, P., Lind, U., Liberg, D., Bamberg, K., and Sigvardsson,
M. (2002). Early B-cell Factor (O/E-1) is a promoter of adipogenisis
and involved in control of genes important for terminal adipocyte
differentiation. Mol Cell Biol 22, 8015-8025.
Cowherd, R. M., Lyle, R. E., and McGehee, R. E., Jr. (1999).
Molecular regulation of adipocyte differentiation. Semin Cell
Dev Biol 10, 3-10.
Rosen, E. D., Walkey, C. J., Puigserver, P., and Spiegelman,
B. M. (2000). Transcriptional regulation of adipogenesis.
Genes Dev 14, 1293-1307.
|
| May
28 |
Johan Staaf: Production of DNA microarrays for gene expression
analysis.
Abstract
Gene expression profiling using microarrays in conjunction
with the availability of complete genomic data for an increasing
number of organisms has introduced a new paradigm in biomedical
research. These achievements revolutionize biology, and offer
a new means for solving problems within the life sciences.
Array technology builds on classical hybridization chemistry.
The novelty lies in the scale: currently, tens of thousands
of gene fragments can be immobilized on single arrays, which
allows the researcher a truly global view of the transcriptome
in a single experiment
The biological complexity can be resolved by
refining sample preparation. Instead of analyzing whole tissue
biopsies, individual cell types can be isolated by laser capture
micro-dissection, by fluorescence-activated cell sorting (FACS)
or antibody coated magnetic beads, allowing only those cells
showing a specific morphology or phenotype to be studied.
This is a major advance, which is likely to rapidly become
a required feature of advanced studies probing into the mechanistic
analysis of cell and tissue differentiation. This increases
the demands on sensitivity of the analytical methods, as well
as on amplification methods to allow array technology to be
applied starting from minimal amounts of RNA.
The Swegene DNA microarray resource center.
The technique had earlier been transferred from the National
Human Genome Research Center at NIH to Dept Oncology and was
moved and allowed to expand in new laboratory space at the
BioMedical Center in conjunction to the Stem Cell Center in
Lund, and is now up running in 2003. The aim of the centre
is to provide south-west Swedish research groups access to
state-of-the-art DNA microarray technology. This has been
accomplished by establishing platforms and expertise for:
- Construction of high quality, high density
microarray chips using different clone platforms.
- Design and construction of large scale PCR
clone libraries through extensive automatisation involving
liquid handling robots.
- Comprehensive RNA expression analysis in the most commonly
used experimental systems (i.e. human, mouse and rat and eventually
in fruit fly, zebra-fish, yeast and other species),
- High-density BAC arrays for comparative genomic
hybridisation analysis of DNA copy gains and losses.
- Preparation of small sample amounts, RNA amplification
(about to begin), labelling and
hybridisation.
- database handling and statistical analysis
in cooperation with the bioinformatics center.
Recommended Reading:
Schulze A. , Downward J. Navigating gene expression using
microarrays - a technology review. Nature Cell Biology, vol
3, August 2001.
|
| June
4 |
Ewa Sitnicka: Receptor ligand
interactions in the regulation of hematopoietic stem cell
fate. Introduction by Sten Eirik Jacobsen
All blood cell lineages arise from common hematopoietic
stem cells (HSC), which due to their capacity to self-renew
maintain hematopoiesis throughout the lifespan of an individual.
The enormous proliferative and differentiation potential of
HSC can be illustrated by 3-5 million mature blood cells produced
in man per second. The molecular mechanism regulating HSC
fate decisions between self-renewal and lineage commitment
remain poorly understood. However, evidence supports that
blood lineage maturation and HSC self-renewal are regulated
in part by hematopoietic cytokines interacting with their
specific surface receptors.
Flt3 (or flk2) is a cytokine tyrosine kinase receptor primarily
expressed at very early stages of hematopoiesis. Mice deficient
in flt3 or flt3 ligand (FL) expression show deficient early
B lymphopoiesis, but myeloid development is not affected.
Although flt3 was cloned based on its expression in the HSC
compartment, we demonstrated recently, that HSC in mouse bone
marrow lack detectable cell surface flt3 expression (Adolfsson
et al, Immunity 2001). To further address the role of flt3
and its ligand in early hematopoietic development we investigated
hematopoiesis in FL-deficient mice, focusing the studies on
the role of FL in regulation of HSC, common lymphoid progenitors
(CLP) and common myeloid progenitors (CMP). Whereas HSC and
common myeloid progenitors are unaffected, FL-deficient mice
show striking reductions in CLP, suggesting a role for FL
in early lymphoid development throughout the generation of
CLP form HSC (Sitnicka et al, Immunity 2002). An indispensable
role of flt3 signaling in B cell development was established
through studies in mice double deficient in FL and Interleukin-7
(IL-7) receptor expression. Although both of these cytokines
have been demonstrated to be important regulators of B cell
development, normal levels of immunoglobulins are produced
in mice deficient in FL or IL-7R expression. However, based
on potent synergistic interactions between these two ligands
in vitro we hypothesized that the concerted action of FL;
acting at very early stages of lymphopoiesis and the lymphoid
lineage specific factor IL-7 might be indispensable for B
cell development in vivo. This hypothesis is supported by
the finding that mice double deficient in FL and IL-7 receptor
expression completely lack mature conventional IgM+ B cells,
IgA+ plasma cells, B1 B cells and fail to produce immunoglobulins.
Recommended literature:
1. Reya, T., Morrison, S. J., Clarke, M. F. & Weissman,
I. L. Stem cells, cancer, and cancer stem cells. Nature 414,
105-11. (2001).
2. Lyman, S. D. & Jacobsen, S. E. c-kit ligand and Flt3
ligand: stem/progenitor cell factors with overlapping yet
distinct activities. Blood 91, 1101-34. (1998).
3. Fry, T. J. & Mackall, C. L. Interleukin-7: from bench
to clinic. Blood 99, 3892-904. (2002).
4. Adolfsson, J. et al. Upregulation of Flt3 expression within
the bone marrow Lin(-)Sca1(+)c- kit(+) stem cell compartment
is accompanied by loss of self-renewal capacity. Immunity
15, 659-69. (2001).
5. Sitnicka, E. et al. Key role of flt3 ligand in regulation
of the common lymphoid progenitor but not in maintenance of
the hematopoietic stem cell pool. Immunity 17, 463-72. (2002).
6. Veiby, O. P., Lyman, S. D. & Jacobsen, S. E. Combined
signaling through interleukin-7 receptors and flt3 but not
c- kit potently and selectively promotes B-cell commitment
and differentiation from uncommitted murine bone marrow progenitor
cells. Blood 88, 1256-65. (1996).
|
| June
11 |
Florian Lueders: Slalom encodes
a PAPS transporter essential for segment polarity and dorsal
ventral axis determination in drosophilia. Introduction by
Udo Haecker
Sulfation of all macromolecules entering the
secretory pathway in higher organisms occurs in the Golgi
and requires the high-energy sulfate donor adenosine 3'-phosphate
5'-phosphosulfate. Here we report the first molecular identification
of a gene that encodes a transmembrane protein required to
transport adenosine 3'-phosphate 5'-phosphosulfate from the
cytosol into the Golgi lumen. Mutations in this gene, which
we call slalom, display defects in Wg and Hh signaling, which
are likely due to the lack of sulfation of glycosaminoglycans
by the sulfotransferase sulfateless. Analysis of mosaic mutant
ovaries shows that sll function is also essential for dorsal-ventral
axis determination suggesting that sll transports the sulfate
donor required for sulfotransferase activity of the dorsal-ventral
determinant pipe.
Keywords: Hedgehog/Glycosaminoglycan/Pipe/Sulfation/Wingless
Introduction
Secreted signaling molecules of the FGF, Hh, TGFb and WNT
families rely on proteoglycans (PGs) for efficient activation
of their respective signaling pathways (reviewed in Perrimon
and Bernfield, 2000). PGs consist of secreted or transmembrane
core proteins to which glycosaminoglycan (GAG) side chains
are attached at specific consensus sites. In Drosophila, the
secreted PG Perlecan (Park et al., 2003), the transmembrane
PG Syndecan (Spring et al., 1994), and two members of the
Glypican-family of glycosylphosphatidylinositol (GPI)-anchored
PGs have been identified. Phenotypes associated with loss
of function mutations of the Glypican-encoding genes dally
(Nakato et al., 1995) and dally-like (dlp) (Baeg et al., 2001;
Khare and Baumgartner, 2000) have revealed the requirement
of these PGs for efficient activation of several signal transduction
pathways.
The function of PGs is critically dependent on the integrity
of the attached GAGs. GAGs are unbranched polysaccharide chains,
which are synthesized on proteoglycan core proteins in the
Golgi and undergo complex modification reactions before the
PG, that they are attached to, is transported to the cell
surface. In the case of Glypican, heparan sulfate (HS) chains,
which consist of a sugar backbone of alternating units of
N-acetyl-glucosamine (GlcNAc) and glucuronic acid (GlcA) are
synthesized on the core protein. The nucleotide sugar substrates
for this reaction are synthesized in the cytoplasm and must
be transported into the Golgi. In Drosophila, the activated
precursor UDP-GlcA is synthesized from UDP-glucose by the
enzymatic activity of the sugarless (sgl) (Binari et al.,
1997; Häcker et al., 1997; Haerry et al., 1997) gene
product, a homolog of mammalian UDP-glucose dehydrogenases.
The gene product of fringe connection (frc), a predicted ER/Golgi
multi-pass transmembrane protein has been shown to transport
UDP-GlcA and UDP-GlcNAc from the cytosol into the Golgi (Goto
et al., 2001; Selva et al., 2001). Mutations in either gene
severely affect the Wg and FGF signaling pathways. Elongation
of the HS chains requires the activity of HS polymerases.
tout-velu (ttv), encodes a protein with homology to the mammalian
HS co-polymerase EXT1and has been demonstrated to be required
specifically for Hh signaling (Bellaiche et al., 1998). Subsequent
to their synthesis, GAGs undergo multiple modifications such
as epimerization and sulfation. Mutations in sulfateless (sfl),
a homologue of vertebrate N-deacetylase/ N-sulfotransferases
(NDST) lead to a severe reduction in the activity of the Wg,
Hh and FGF signaling pathways (Lin et al., 1999; Lin and Perrimon,
1999). A characteristic feature of all mutations in genes
involved in GAG biosynthesis is, that their segment polarity
phenotypes can be rescued by ectopic expression of wg or hh,
suggesting that GAGs are not essential components of the respective
signaling cascades but accessory factors most likely required
for the proper distribution of extracellular signaling molecules
throughout morphogenetically active tissues in vivo.
GAGs have also been proposed to play a role
in the determination of the dorsal-ventral (D/V) axis of the
Drosophila embryo (Sen et al., 1998). The D/V polarity of
the embryo is established during oogenesis by asymmetric expression
of the key D/V determinant pipe (pip) in the follicle cell
epithelium. pip expression in the ventral follicle cell layer
is necessary and sufficient to trigger a serine-protease cascade
in the perivitelline space, which leads to the generation
of an active ligand for the transmembrane receptor Toll (Tl).
Activation of Tl on the ventral side of the embryo results
in a gradient of nuclear localization of the transcription
factor Dorsal, which patterns the D/V axis (reviewed in Amiri
and Stein, 2002). Based on sequence similarity to a family
of vertebrate enzymes, and its localization in the Golgi apparatus,
pip has been hypothesized to encode a heparansulfate 2-O-sulfotransferase
(HSST). However, neither the enzymatic activity nor the substrate
specificity of pip have been demonstrated directly.
Sulfation of secreted molecules occurs in the
Golgi and requires the high-energy sulfate donor adenosine
3'-phosphate 5'-phosphosulfate (PAPS) to be present within
that organelle. In Drosophila, PAPS is synthesized in the
cytoplasm by PAPS-synthetase (Jullien et al., 1997), which
incorporates both ATP-sulfurylase and Adenosine 5'-phosphosulfate-kinase
(APS-kinase) activity. PAPS must be transported into the Golgi
thereafter (Lyle et al., 1994) to serve as a substrate for
sulfotransferases. Here, we report the first molecular identification
and functional characterization of a PAPS-transporter. Mutations
in this gene, which we call slalom (sll), are associated with
defects in multiple signaling pathways, including Wg and Hh
signaling. A phenotypic analysis suggests that the effects
of sll on signal transduction are caused by its requirement
for GAG modification. We present evidence that sll is also
required to supply PAPS to the machinery initiating the establishment
of embryonic D/V polarity, supporting the view that Pipe protein
is a sulfotransferase.
|
| November
25 |
Carlos Rovira: Functional genomic approach
for the study of non-coding RNAs
Cells contain a variety of noncoding RNAs (ncRNA) that do
not function as messenger RNA. This group includes tRNAs,
rRNAs and also regulatory RNAs that influence the expression
of other genes. In the last four years, it has become increasingly
apparent that noncoding RNAs belonging to the last named class
are impressively diverse. They have been proposed to participate
in the defense of the genome by targeting and
destroying foreign or invading nucleic acids
but also in other more general mechanisms of gene regulation.
The functions described for ncRNAs thus far are extremely
varied and
include: transcriptional regulation (gene silencing/chromosome
inactivation), chromosome replication, RNA processing and
modification, mRNA stability and translation and even protein
degradation and translocation. A common denominator for many
of these processes is that apparently they are functional
at early stages of embryonic development and cell differentiation.
Recent reports indicate that ncRNA are far more abundant
and important than initially imagined (estimated from hundreds
to thousands per genome), and therefore raised several fundamental
questions:
- How many regulatory RNAs are encoded by a genome?.
- Given the absence in many cases of a diagnostic open reading
frame,
how can these genes be identified?
- How can all their functions be elucidated?
- What is the real impact of regulatory RNAs in both biology
and in
human diseases?
To answer these questions we set out to adapt or develop
new techniques which would allow us to get new insights in
what seems to be a fundamental question in modern biology.
|
|
|